Amidst a globally aging population and escalating healthcare spending due to increased infectious and chronic diseases, the demand for advanced healthcare solutions remains strong. So, I think robust biotech stocks Genmab A/S (GMAB), Jazz Pharmaceuticals plc (JAZZ), and Exelixis, Inc. (EXEL) could be ideal additions to elevate one’s portfolio.
The biotech landscape is witnessing a transformative shift driven by significant progress in genetics, a rise in collaborative initiatives among life sciences companies, and a notable surge in the utilization of digital assessment and treatment methods.
